Drug Trial News RSS Feed - Drug Trial News

Eli Lilly to present Phase III PROCLAIM trial results at ASCO Annual Meeting

Eli Lilly to present Phase III PROCLAIM trial results at ASCO Annual Meeting

Eli Lilly and Company announced final results of the Phase III PROCLAIM trial that will also be discussed in an oral presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. [More]

First European approval of drug to treat genetic kidney disease ADPKD

Otsuka Pharmaceutical Co., Ltd. announced that the European Commission has granted marketing authorisation for JINARC® (tolvaptan) for the treatment of ADPKD in adults who have chronic kidney disease (CKD) stage one to three at initiation of treatment with evidence of rapidly progressing disease [More]
Amgen announces AMG 416 Phase 3 results for treatment of secondary hyperparathyroidism in CKD patients

Amgen announces AMG 416 Phase 3 results for treatment of secondary hyperparathyroidism in CKD patients

Amgen today announced pooled data from two pivotal Phase 3, global, randomized, placebo-controlled trials evaluating AMG 416, a novel calcimimetic, for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease (CKD) receiving hemodialysis. [More]
Array BioPharma presents clinical data of BRAF, MEK and HER2 drugs at 2015 ASCO Annual Meeting

Array BioPharma presents clinical data of BRAF, MEK and HER2 drugs at 2015 ASCO Annual Meeting

Array BioPharma Inc. today announced presentations on encorafenib, binimetinib and selumetinib (licensed to AstraZeneca) at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held May 29 – June 2, 2015 in Chicago, Illinois. [More]
Monoclonal antibody nivolumab improves survival rates of melanoma patients

Monoclonal antibody nivolumab improves survival rates of melanoma patients

The monoclonal antibody nivolumab has shown promise as a therapeutic agent, particularly by improving the survival rates of melanoma patients. Jeffrey S. Weber, M.D., Ph.D., director of the Donald A. Adam Comprehensive Melanoma Research Center at Moffitt Cancer Center will be presenting data from a retrospective analysis of the safety of nivolumab in 4 ongoing phase I-III studies in melanoma patients at the 2015 American Society of Clinical Oncology Annual Meeting in Chicago. [More]
MEDI4736 and tremelimumab combination shows acceptable safety, potential efficacy in NSCLC patients

MEDI4736 and tremelimumab combination shows acceptable safety, potential efficacy in NSCLC patients

Advanced non-small cell lung cancer (NSCLC) patients have few effective treatment options and low 5-year survival rates. The checkpoint inhibitors MEDI4736 and tremelimumab have both demonstrated acceptable safety and potential efficacy when used as single-agents in several different types of cancer. [More]
JAK2 inhibitor ruxolitinib shows promise in treating CMML patients

JAK2 inhibitor ruxolitinib shows promise in treating CMML patients

Chronic myelomonocytic leukemia (CMML) is a rare type of myelodysplastic, myeloproliferative neoplasm characterized by increased numbers of peripheral monocytes and less than 20 percent blasts. CMML has few treatment options and patients only survive on average for 12 to 24 months. [More]
Green tea components may help prevent prostate cancer development in at-risk men

Green tea components may help prevent prostate cancer development in at-risk men

Prostate cancer is the second most common type of cancer in men and is predicted to result in an estimated 220,00 cases in the United States in 2015. In recent years, an emphasis has been placed on chemoprevention - the use of agents to prevent the development or progression of prostate cancer. [More]
Janssen, Bayer HealthCare initiate CALLISTO program to study rivaroxaban in patients with active cancer

Janssen, Bayer HealthCare initiate CALLISTO program to study rivaroxaban in patients with active cancer

Janssen Pharmaceuticals, Inc. and its development partner, Bayer HealthCare, today announced the initiation of CALLISTO, a new comprehensive clinical research program for their novel oral anticoagulant, rivaroxaban, in patients with active cancer. The studies are evaluating the medicine for the prevention and treatment of life-threatening blood clots in patients with a wide range of cancer types. [More]
PDS Biotechnology announces positive results from PDS0101 Phase I trial in pre-cervical cancer patients

PDS Biotechnology announces positive results from PDS0101 Phase I trial in pre-cervical cancer patients

PDS Biotechnology Corp. announces preliminary data showing that PDS0101, a cancer immunotherapy treatment targeting HPV-16, has generated strong T-cell responses in pre-cervical cancer patients. [More]
Data supporting anti-cancer potential of Biscayne’s GHRH antagonist to be discussed at ASCO Annual Meeting

Data supporting anti-cancer potential of Biscayne’s GHRH antagonist to be discussed at ASCO Annual Meeting

Biscayne Pharmaceuticals, Inc., today announced that data supporting the anti-cancer potential of its growth hormone-releasing hormone (GHRH) technology will be discussed in a poster presentation at the 2015 ASCO Annual Meeting. [More]
Clementia Pharmaceuticals commences multi-center study of patients with fibrodysplasia ossificans progressiva

Clementia Pharmaceuticals commences multi-center study of patients with fibrodysplasia ossificans progressiva

Clementia Pharmaceuticals, Inc. today announced that it has commenced enrollment in the second part (Part B) of its natural history study in patients with fibrodysplasia ossificans progressiva (FOP), a rare, severely disabling congenital myopathy characterized by painful, recurrent episodes of soft tissue swelling (flare-ups) that result in the formation of new, abnormal (heterotopic) bone in muscles, tendons and ligaments. [More]
Amgen to present clinical data on multiple blood cancer treatments at EHA 2015

Amgen to present clinical data on multiple blood cancer treatments at EHA 2015

Amgen today announced that it will present data from multiple Kyprolis (carfilzomib) for Injection, BLINCYTO (blinatumomab), oprozomib and Nplate (romiplostim)‎ studies at the 20th Congress of the European Hematology Association taking place in Vienna, June 11 - 14, 2015. [More]
Earlier antiretroviral treatment benefits HIV-infected individuals

Earlier antiretroviral treatment benefits HIV-infected individuals

A major international randomized clinical trial has found that HIV-infected individuals have a considerably lower risk of developing AIDS or other serious illnesses if they start taking antiretroviral drugs sooner, when their CD4+ T-cell count--a key measure of immune system health--is higher, instead of waiting until the CD4+ cell count drops to lower levels. Together with data from previous studies showing that antiretroviral treatment reduced the risk of HIV transmission to uninfected sexual partners, these findings support offering treatment to everyone with HIV. [More]
Brigatinib drug shows promise against ALK+ non-small cell lung cancer in phase I/II clinical trial

Brigatinib drug shows promise against ALK+ non-small cell lung cancer in phase I/II clinical trial

Phase I/II clinical trial results reported at the American Society for Clinical Oncology (ASCO) Annual Meeting 2015 show promising results for investigational drug brigatinib against ALK+ non-small cell lung cancer (NSCLC), with 58 of 78 ALK+ patients responding to treatment, including 50 of 70 patients who had progressed after previous treatment with crizotinib, the first licensed ALK inhibitor. [More]
Positive clinical data of CytRx's aldoxorubicin to be presented at ASCO 2015

Positive clinical data of CytRx's aldoxorubicin to be presented at ASCO 2015

CytRx Corporation, a biopharmaceutical research and development company specializing in oncology, today announced an upcoming poster presentation regarding its lead drug candidate, aldoxorubicin, at the 2015 American Society of Clinical Oncology Annual Meeting, which is being held May 29 - June 2, 2015 in Chicago. [More]
Soy supplement does not improve lung function, clinical outcomes in patients with asthma

Soy supplement does not improve lung function, clinical outcomes in patients with asthma

Although some data have suggested that supplementation with soy isoflavone may be an effective treatment for patients with poor asthma control, a randomized trial that included nearly 400 children and adults found that use of the supplement did not result in improved lung function or clinical outcomes, including asthma symptoms and episodes of poor asthma control, according to a study in the May 26 issue of JAMA. [More]
Biomedical Technologies (BT), now part of Alfa Aesar enhances lipoprotein manufacturing capabilities

Biomedical Technologies (BT), now part of Alfa Aesar enhances lipoprotein manufacturing capabilities

Preparative ultracentrifuges are used in biology for gradient separations, where the molecules in a sample are separated using a substance of graduated density, such as salt gradients for proteins... [More]
AbbVie announces new results from Phase 3 GIFT-I study in GT1b HCV infected Japanese patients

AbbVie announces new results from Phase 3 GIFT-I study in GT1b HCV infected Japanese patients

AbbVie presented new results from the Phase 3 GIFT-I study of its investigational, all-oral, interferon (IFN)- and ribavirin (RBV)-free, two direct-acting antiviral treatment with ombitasvir/paritaprevir/ritonavir at the Annual Meeting of the Japan Society of Hepatology in Kumamoto, Japan. [More]
New stem-cell based therapy provides pain relief, reduces severity of RDEB in children

New stem-cell based therapy provides pain relief, reduces severity of RDEB in children

Promising results from a trial of a new stem-cell based therapy for a rare and debilitating skin condition have been published in the Journal of Investigative Dermatology. The therapy, involving infusions of stem cells, was found to provide pain relief and to reduce the severity of this skin condition for which no cure currently exists. [More]
Advertisement
Advertisement